Regulation of FGF21 by Nutritional Challenges

NCT ID: NCT00968747

Last Updated: 2023-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine how acute nutritional challenges affect levels of several proteins involved in metabolism. These proteins will be measured in blood and fat tissue.

This study will have several aims.

One aim is to examine the effect of 72 hours of fasting on fibroblast growth factor-21 (FGF-21) levels. Participants will spend 3 days and nights in the Clinical Research Center at the Beth Israel Deaconess Medical Center in Boston, MA. Daily blood samples will be taken. Two fat samples will be taken prior to and at the end of the fast. A subset of participants will also have two MRIs, one prior to and one at the end of the fast. We will study healthy adults and obese adults with liver-biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD). THIS STUDY ARM IS CURRENTLY NOT RECRUITING

Another aim is to examine the effect of low-calorie diet on FGF-21 levels. Subjects will follow a hypocaloric diet that will be designed to achieve 3-5% weight loss. We will enroll participants with liver-biopsy-diagnosed non-alcoholic fatty liver disease. Participants will report weekly to the Clinical Research Center at Beth Israel Deaconess Medical Center for weight measurements. Blood will be drawn before and after the weight loss. Participants will also have an MRI before and after the weight loss.

THIS ARM IS CURRENTLY NOT RECRUITING

Another aim of the study is to examine the effect of acute ingestion of glucose, fructose, and other sugars on serum FGF21 levels. Subjects in this study will be lean volunteers and individuals with metabolic syndrome.

THIS ARM IS CURRENTLY RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to 5 different sweet beverages, separated by 2 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fasting Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fasting (Healthy).

Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).

Group Type EXPERIMENTAL

Fasting

Intervention Type BEHAVIORAL

Participants will fast for 72 hours and may consume only water and vitamins.

Fasting

Intervention Type BEHAVIORAL

Participants will fast for 72 hours and may consume only water and vitamins.

Fasting (NAFLD)

Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.

Group Type EXPERIMENTAL

Fasting

Intervention Type BEHAVIORAL

Participants will fast for 72 hours and may consume only water and vitamins.

Hypocaloric diet (NAFLD)

Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.

Group Type EXPERIMENTAL

Diet

Intervention Type BEHAVIORAL

Participants will follow a low-calorie diet until they lose 3-5% of their body weight.

Oral carbohydrate challenge

Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours

Group Type EXPERIMENTAL

oral carbohydrate challenge

Intervention Type DIETARY_SUPPLEMENT

Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fasting

Participants will fast for 72 hours and may consume only water and vitamins.

Intervention Type BEHAVIORAL

Fasting

Participants will fast for 72 hours and may consume only water and vitamins.

Intervention Type BEHAVIORAL

Diet

Participants will follow a low-calorie diet until they lose 3-5% of their body weight.

Intervention Type BEHAVIORAL

oral carbohydrate challenge

Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-50 years
* Body Mass Index 21-26 kg/m\^2
* Ability to give informed consent
* Ability to follow verbal and written instructions in English


* Age 18-60
* BMI 25-45 kg/m\^2
* Known nonalcoholic fatty liver disease based on liver biopsy
* Ability to give informed consent
* Ability to follow verbal and written instructions in English

Exclusion Criteria

* Type 1 or Type 2 diabetes mellitus diagnosed according to the American Diabetes Association criteria
* Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
* Tobacco, marijuana, or intravenous drug use within 1 year of screening visit
* Recent weight change (\>3 kg within 6 months of screening visit)
* Malignancy treated with chemotherapy within past 3 years
* History of depression, psychosis, or other psychiatric illness requiring hospitalization
* History of hyperthyroidism
* Renal insufficiency (creatinine clearance \< 50 ml/min)
* Transaminases \> 2X above the normal range
* Known liver disease
* Pregnancy within 12 months of screening visit
* Lactation within 12 months of screening visit
* Failure to use medically approved contraceptive methods (oral contraceptive, 2 barrier methods, surgical sterilization)
* History of an eating disorder (anorexia, bulimia, or laxative abuse)
* History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
* New diagnosis of hypothyroidism within 1 year of screening visit or change in dose of thyroid hormone within 3 months of screening visit
* History of alcohol abuse within the past 3 years
* History of keloid formation
* History of allergy to lidocaine or marcaine
* Use of plavix, coumadin, or heparin

72-hour fast or hypocaloric diet in subjects with non-alcoholic fatty liver disease (NAFLD) (Study Arms B \& C):


* Type I diabetes mellitus diagnosed according to the American Diabetes Association criteria or Type II diabetes mellitus with A1c \> 7.5% or taking metformin or thiazolidinediones
* Coronary Heart Disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
* Uncontrolled hypertension (BP \> 150/90 mmHg on or off antihypertensive medication)
* Tobacco, marijuana, or intravenous drug use within 1 year of screening visit
* Recent weight change (\> 3 kg within 6 months of screening visit)
* Malignancy treated with chemotherapy within the past 3 years
* History of depression, psychosis, or other psychiatric illness requiring hospitalization
* History of hypo or hyperthyroidism
* Renal insufficiency (creatinine clearance \< 50 ml/min)
* Pregnancy within 12 months of screening visit
* Lactation within 12 months of screening visit
* Failure to use medically approved contraceptive methods (oral contraceptive, 2 barrier methods, surgical sterilization)
* History of an eating disorder (anorexia, bulimia, or laxative abuse)
* History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
* New diagnosis of hypo or hyperthyroidism within 1 year of screening visit or change in dose of thyroid hormone within 3 months of screening visit
* History of alcohol abuse within the past 3 years
* Cardiac pacemaker or aneurysm clips
* Metal implants in the body (pins, plates, shrapnel, intact bullets, IUD)
* Claustrophobia
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jody Dushay

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jody Dushay, MD

Role: PRINCIPAL_INVESTIGATOR

Beth Israel Deaconess Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009P-000073

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Migalastat Food Effect Study
NCT01489995 COMPLETED PHASE1
Quantitative Liver Function Tests Using Cholates
NCT01907074 ACTIVE_NOT_RECRUITING PHASE2